Brentuximab vedotin as monotherapy for unresectable breast implant ‐associated anaplastic large cell lymphoma

We present a case of u nresectable BI‐ALCL, which was successfully treated with brentuximab vedotin. Key Clinical MessageBI ‐ALCL is a rare CD30+ T‐cell malignancy, which is known to complicate textured breast implants. The CD30‐targeting immunoconjugate, brentuximab vedotin, has been suggested for invasive BI‐ALCL; however, its efficacy for unresectable BI‐ALCL has not been demonstrated. We present a case of u nresectable BI‐ALCL, which was successfully treated with brentuximab vedotin.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research